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Objectives The purpose of this study was to examine the incremental value of copeptin for rapid rule out of acute myocar-
dial infarction (AMI).
Background The rapid and reliable exclusion of AMI is a major unmet clinical need. Copeptin, the C-terminal part of the vaso-
pressin prohormone, as a marker of acute endogenous stress may be useful in this setting.
Methods In 487 consecutive patients presenting to the emergency department with symptoms suggestive of AMI, we
measured levels of copeptin at presentation, using a novel sandwich immunoluminometric assay in a blinded
fashion. The final diagnosis was adjudicated by 2 independent cardiologists using all available data.
Results The adjudicated final diagnosis was AMI in 81 patients (17%). Copeptin levels were significantly higher in AMI
patients compared with those in patients having other diagnoses (median 20.8 pmol/l vs. 6.0 pmol/l,
p  0.001). The combination of troponin T and copeptin at initial presentation resulted in an area under the
receiver-operating characteristic curve of 0.97 (95% confidence interval: 0.95 to 0.98), which was significantly
higher than the 0.86 (95% confidence interval: 0.80 to 0.92) for troponin T alone (p  0.001). A copeptin level
14 pmol/l in combination with a troponin T 0.01 g/l correctly ruled out AMI with a sensitivity of 98.8% and
a negative predictive value of 99.7%.
Conclusions The additional use of copeptin seems to allow a rapid and reliable rule out of AMI already at presentation and may
thereby obviate the need for prolonged monitoring and serial blood sampling in the majority of patients. (Advanta-
geous Predictors of Acute Coronary Syndromes Evaluation [APACE]; NCT00470587) (J Am Coll Cardiol 2009;54:
60–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.076o
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Tcute myocardial infarction (AMI) is the major cause of
eath and disability worldwide, with an ongoing increase in
ncidence. Approximately 15 million patients per year
resent to the emergency department (ED) with chest pain
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urope (1). Rapid assessment of these patients is critical to
irect further diagnostic and therapeutic strategies. Electro-
ardiography (ECG) and cardiac troponin form the current
iagnostic cornerstones and complement clinical assessment
n current AMI guidelines (2,3). They allow for a rule in of
MI within the first 3 h after presentation in the majority
f patients (4) and offer the opportunity to initiate appro-
riate, evidence-based treatment (5,6).
The vast majority of patients presenting to the ED with
uspected AMI, however, finally prove not to have AMI (7).
urrent rule out of AMI is time-consuming and expensive
8). One-quarter to one-third of patients with AMI present
ithout significant ECG changes indicative of acute isch-
mia; therefore, ECG is of little help to rule out AMI (7,9).
he major limitation of current troponin assays is a sensi-ivity deficit at presentation due to a delayed increase of
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June 30, 2009:60–8 Copeptin for the Rapid Rule Out of AMIirculating levels (10). Exclusion of AMI consequently
equires prolonged monitoring over 6 to 9 h and serial blood
ampling. This procedure contributes to overcrowding in
he ED, and the associated costs probably exceed several
illion U.S. dollars each year (11,12). The rapid and reliable
ule out of AMI, therefore, represents one of the large
nmet needs in clinical medicine.
The arginine-vasopressin system plays a crucial role in the
egulation of the individual endogenous stress response (13).
evels of arginine-vasopressin have been shown to be
levated in heart failure (14) and in different states of shock
15), but investigation of the arginine-vasopressin system
as been limited so far because arginine-vasopressin is
nstable (half-life: 5 to 15 min) and largely attached to
latelets (16,17). Copeptin, the c-terminal part of the
asopressin prohormone, is secreted stoichiometrically with
rginine-vasopressin from the neurohypophysis and is much
ore stable, thus overcoming the limitations and difficulties
f assessing the arginine-vasopressin system (18). In a recent
tudy, copeptin was markedly elevated in patients after AMI
nd predicted adverse outcome (19); however, nothing is
nown about the diagnostic value of copeptin in AMI.
We hypothesized that the combination of a marker of
ardiac necrosis, such as troponin, with a pathophysiologi-
ally different biomarker reflecting acute endogenous stress,
uch as copeptin, might allow for a rapid and accurate rule
ut of AMI already at initial presentation without serial
lood sampling.
ethods
tudy design and population. From April 2006 to Sep-
ember 2007, a total of 492 consecutive patients presenting
o the ED of the University Hospital Basel, Switzerland,
ith symptoms suggestive of AMI such as chest pain and
ngina pectoris with onset or peak within the last 12 h were
ecruited in this prospective cohort study. Patients with
erminal kidney failure requiring dialysis were excluded. The
tudy was performed according to the principles of the
eclaration of Helsinki and approved by the local ethics
ommittee. Written informed consent was obtained from all
articipating patients.
outine clinical assessment. All patients underwent an
nitial clinical assessment that included clinical history,
hysical examination, 12-lead ECG, continuous ECG
onitoring, pulse oximetry, standard blood tests, and chest
adiography. Troponin T, the myocardial band (MB) frac-
ion of creatine kinase and myoglobin, were measured at
resentation and after 3 and 6 to 9 h, as long as clinically
ndicated. The timing and treatment of patients were left to
he discretion of the attending physicians.
djudicated final diagnosis. To determine the causal di-
gnosis at presentation for each patient, 2 independent
ardiologists blinded to the results of copeptin reviewed all
vailable medical records (including patient history, physical
xamination, results of laboratory and radiologic testing, sCG, echocardiography, cardiac
xercise test, coronary angiogra-
hy) pertaining to the patient
rom the time of ED presenta-
ion to 60-day follow-up. In di-
gnostic disagreement, cases
ere reviewed and adjudicated in
onjunction with a third cardiol-
gist. AMI was defined as rec-
mmended in current guidelines
2,3). In brief, AMI was diag-
osed when there was evidence
f myocardial necrosis in a clini-
al setting consistent with myo-
ardial ischemia. Necrosis was diagnosed by a rising and/or
alling pattern of troponin T with at least 1 value above the
9th percentile, with an imprecision of 10% (20). For the
roponin T assay, the lower limit of detection is 0.01 g/l.
hus, to manifest a rising pattern, patients with normal
nitial values had to increase troponin T levels to the cutoff
evel of 0.04 g/l to fulfill AMI criteria (21). Unstable
ngina was diagnosed in patients with normal troponin T
evels and typical angina at rest, a sudden increase in
pisodes of a previously stable angina, in cases of positive
ardiac exercise testing or cardiac catheterization with cor-
nary arteries found to have stenosis of 70%, and in
mbiguous cases in which follow-up information revealed
MI or a sudden unexpected cardiac death within 60 days.
re-defined further diagnostic categories included cardiac
ut not coronary symptoms (e.g., perimyocarditis, tachyar-
hythmias) and noncardiac symptoms. If AMI was excluded
n the ED, but no sufficient further diagnostic procedures
ere performed for conclusive diagnosis, symptoms were
lassified as of unknown origin.
iochemical analysis. Troponin T was determined imme-
iately using a 1-step enzyme immunoassay based on
lectrochemiluminescence technology. The MB fraction of
reatine kinase (by mass assay) and myoglobin were mea-
ured by immunoassays (all Elecsys 2010, Roche Diagnos-
ics, Mannheim, Germany).
Blood samples for determination of copeptin were col-
ected at presentation to the ED in all patients, and as long
s there was diagnostic uncertainty, after 1, 2, 3, and 6 h
nto tubes containing potassium ethylenediaminetetra-
cetic acid. After centrifugation, samples were frozen at
80°C until assayed in a blinded fashion in a single batch
sing a novel commercial sandwich immunolumino-
etric assay (B.R.A.H.M.S. LUMItest CT-proAVP,
.R.A.H.M.S AG, Hennigsdorf/Berlin, Germany), as de-
cribed in detail elsewhere (18). Since this initial publica-
ion, the assay was modified as follows: the capture antibody
as replaced by a murine monoclonal antibody directed to
mino acids 137-144 (GPAGAL) of proAVP. This mod-
fication improved the sensitivity of the assay. The lower
etection limit was 0.4 pmol/l, and the functional assay
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
AUC  area under the
curve
CI  confidence interval
ECG  electrocardiography
ED  emergency
department
ROC  receiver-operator
characteristicensitivity (20% interassay CV) was 1 pmol/l. The
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Copeptin for the Rapid Rule Out of AMI June 30, 2009:60–8edian copeptin level in 200 healthy persons was 3.7 pmol/l
nd the 97.5 percentile was 16.4 pmol/l.
Glomerular filtration rate was calculated using the abbre-
iated Modification of Diet in Renal Disease formula (22).
CG analysis. All 12-lead admission ECGs were assessed
n a core laboratory by internal medicine specialists blinded
o the clinical and biochemical patients’ details. The ECG
anifestations indicative of AMI were defined as recom-
ended in current guidelines (2,3).
tatistical analysis. Continuous variables are presented as
ean  SD or median (with interquartile range [IQR]),
ategorical variables as numbers and percentages. Continu-
us variables were compared with the Mann-Whitney U
est and categorical variables using the Pearson chi-square
est. Correlations among continuous variables were assessed
ith the use of the Spearman rank-correlation coefficient.
ogistic regression was used to combine troponin T and
opeptin in the diagnosis of AMI and to adjust for other
aseline variables. Receiver-operator characteristic (ROC)
urves were constructed to assess the sensitivity and speci-
city throughout the concentrations of troponin T and
opeptin and to compare the ability of troponin T, copeptin,
nd its combination to diagnose AMI. Comparison of areas
nder the ROC curves was performed as recommended by
Baseline Characteristics of the Patients
Table 1 Baseline Characteristics of the Pat
Characteristic
Age, yrs
Male
Risk factors
Hypertension
Hyperlipidemia
Diabetes mellitus
Current smoking
History of smoking
History
Coronary artery disease
Previous myocardial infarction
Previous revascularization
Peripheral artery disease
Previous stroke
Vital status
Heart rate, beats/min
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Primary electrocardiographic findings
Left bundle branch block
ST-segment elevation
ST-segment depression
T-wave inversion
No significant electrocardiographic abnormalities
Laboratory assessment
Estimated glomerular filtration rate, ml/min/1.73 m2
Management of patients
OutpatientsValues are presented as n (%) or mean  SD.eLong (23). All hypothesis testing was 2-tailed, and a
value of 0.05 was considered statistically significant.
tatistical analyses were performed using SPSS for Win-
ows 15.0 (SPSS Inc., Chicago, Illinois) and MedCalc
.6.4.0 (MedCalc Software, Mariakerke, Belgium).
esults
haracteristics of patients. Of the 492 consecutive pa-
ients enrolled in the study, 5 were excluded from the
nalysis because of missing copeptin or troponin T values.
aseline characteristics of the remaining 487 patients are
hown in Table 1. The adjudicated final diagnosis was AMI
n 17% of patients, unstable angina in 17%, cardiac symp-
oms of origin other than coronary artery disease in 13%,
oncardiac symptoms in 43%, and symptoms of unknown
rigin in 11%. Of the 81 patients with AMI, 30 (37%) were
iagnosed having ST-segment elevation MI and 51 (63%)
s having non–ST-segment elevation MI.
roponin T levels. Among patients with AMI, troponin
at presentation was 0.01 g/l in 25% and below the
ecision limit of 0.04 g/l in 35% of patients. Of the 406
atients without AMI, 5.9% had a troponin T at presenta-
atients
487)
Acute Myocardial Infarction
p ValueYes (n  81) No (n  406)
 17 68 15 61 17 0.001
(66) 58 (72) 263 (65) 0.24
(58) 54 (67) 228 (56) 0.08
(39) 35 (43) 157 (39) 0.45
(16) 13 (16) 64 (16) 0.95
(26) 26 (32) 101 (25) 0.18
(32) 24 (30) 130 (32) 0.67
(34) 27 (33) 139 (34) 0.88
(24) 20 (25) 97 (24) 0.88
(27) 18 (22) 113 (28) 0.30
(7) 5 (6.2) 28 (6.9) 0.81
(7) 8 (9.9) 28 (6.9) 0.35
 20 80 21 79 19 0.78
 25 141 31 144 24 0.09
 15 87 18 87 14 0.83
(2.7) 4 (4.9) 9 (2.2) 0.17
(8.0) 29 (36) 10 (2.5) 0.001
(8.6) 12 (15) 30 (7.4) 0.03
(7.4) 13 (16) 23 (5.7) 0.001
(73) 23 (28) 334 (82) 0.001
 30 85 30 97 29 0.001
(47) 2 (2.5) 227 (56) 0.001ients
All P
(n 
62
321
282
192
77
127
154
166
117
131
33
36
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June 30, 2009:60–8 Copeptin for the Rapid Rule Out of AMIion 0.01 g/l and 2.2% above the decision limit for AMI
f 0.04 g/l.
opeptin levels. As shown in Figure 1A, copeptin levels
ere significantly higher in patients with AMI as compared
ith patients having other diagnoses (AMI, median 20.8
mol/l, IQR 7.9 to 60.6 pmol/l; unstable angina, median
.4 pmol/l, IQR 4.0 to 12.3 pmol/l; cardiac symptoms of
rigin other than coronary artery disease, median 7.9
mol/l, IQR 3.5 to 20.5 pmol/l, noncardiac symptoms,
edian 5.4 pmol/l, IQR 3.3 to 10.4 pmol/l; symptoms of
nknown origin, median 7.8 pmol/l, IQR 4.2 to 13.0
mol/l; p  0.001 for all comparisons with AMI patients).
one of the other groups differed significantly from each
ther. Copeptin levels differed significantly between pa-
ients with ST-segment elevation MI (median 45.5 pmol/l,
QR 21.0 to 123 pmol/l), non–ST-segment elevation MI
median 11.7 pmol/l, IQR 6.2 to 50.8 pmol/l), and unstable
ngina (Fig. 1B).
Among the 81 patients with AMI, copeptin was signif-
cantly higher in patients with an initial troponin T level
0.01 g/l (median 75.9 pmol/l, IQR 26.0 to 158.3
mol/l) than in patients with a troponin T level 0.01 g/l
median 11.7 pmol/l, IQR 6.2 to 45.5 pmol/l; p  0.001).
urthermore, in patients with AMI, there was a significant
nverse correlation between copeptin and the time since
nset of symptoms (r  0.44, p  0.001), whereas
roponin T was positively correlated with the time since
nset of symptoms (r  0.51, p  0.001). If patients with
MI were divided into groups according to the time since
nset of symptoms, copeptin levels at admission were
ighest in the group of patients presenting 0 to 4 h after
A
200
150
100
50
0
AMI Unstable
Angina
Cardiac but
not CAD
Non-cardiac unknow
Figure 1 Copeptin Levels at Presentation
Copeptin levels at presentation to the emergency department (A) in all patients accor
Boxes represent interquartile ranges and whiskers display ranges (without outliers furnset of symptoms (median 52.5 pmol/l, IQR 13.6 to 110.8
mol/l) with a falling pattern thereafter (5 to 10 h, median
0.8 pmol/l, IQR 12.2 to 69.4 pmol/l; 10 h, median 9.9
mol/l, IQR 5.4 to 25.5 pmol/l; p  0.001). Troponin T
evels were lowest in patients presenting earliest and rising
ith increasing time since onset of symptoms (0 to 4 h,
edian 0.01 g/l, IQR 0.01 to 0.08 g/l; 5 to 10 h, median
.11 g/l, IQR 0.02 to 0.38 g/l;10 h, median 0.18 g/l,
QR 0.06 to 0.61g/l; p  0.001) (Fig. 2).
The distribution of several baseline characteristics across
opeptin quartiles are shown in Table 2. Patients in the
ifferent quartiles of copeptin were comparable regarding
ost baseline characteristics, including history of coronary
rtery disease and history of MI. Patients in the highest
uartile were older, more often male, and more often had
ypertension, a higher body mass index, and a worse renal
unction. In a subgroup of 25 AMI patients with diagnostic
ncertainty until 6 h after presentation, serial sampling was
erformed. Copeptin kinetics in the subgroup of 25 AMI
atients were analyzed and compared to a group of 83
atients with noncardiac symptoms, in whom samples were
vailable at presentation, after 3 h, and after 6 h as well
AMI median copeptin values were 14.1 pmol/l at presen-
ation, 7.7 pmol/l at 3 h, and 11.0 pmol/l at 6 h; vs. those
f noncardiac patients: 5.6 pmol/l at presentation, 5.1
mol/l at 3 h, and 5.4 pmol/l at 6 h).
Figure 3 describes levels of copeptin according to ECG
ndings and troponin T status at presentation. If troponin
was 0.01 g/l at presentation, copeptin was signifi-
antly higher in patients with AMI than in patients with
ther diagnoses, regardless of presence or absence and type
B
200
150
100
50
0
STEMI NSTEMI Unstable Angina
adjudicated final diagnosis and (B) in patients with acute coronary syndrome only.
an 1.5 interquartile ranges from the end of the box). AMI  acute myocardial infarc-n
ding to
ther th
tion; CAD  coronary artery disease; NSTEMI  non–ST-segment elevation myocardial infarction; STEMI  ST-segment elevation myocardial infarction.
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Copeptin for the Rapid Rule Out of AMI June 30, 2009:60–8f ECG abnormalities (p  0.001 for groups with no
ignificant ECG abnormalities and ST-segment elevation/
eft bundle branch block not known to be old; p 0.016 for
roup with ST-segment depression/T-wave inversion).
owever, if patients presented late after onset of symptoms
nd troponin T was 0.01 g/l already at presentation, no
ignificant differences in copeptin levels were observed
etween patients with and without AMI.
Figure 2 Copeptin and Troponin T Levels at Presentation
in Relation to Time Since Onset of Symptoms
Median levels of copeptin (blue bars) and troponin T (green bars) at presentation
to the emergency department in patients with the adjudicated final diagnosis of
acute myocardial infarction according to the time since onset of symptoms.
aseline Characteristics of the Patients in Relation to Copeptin Qu
Table 2 Baseline Characteristics of the Patients in Relation to
Characteristic
Quartile 1
<3.8 pmol/l
(n  122)
Qu
3.82–
(n
Age, yrs 58 17 5
Male 61 (50) 83
Risk factors
Hypertension 65 (53) 61
Hyperlipidemia 44 (36) 53
Diabetes mellitus 15 (12) 18
Current smoking 33 (27) 37
History of smoking 29 (24) 39
History
Coronary artery disease 36 (30) 40
Previous myocardial infarction 24 (20) 27
Previous revascularization 29 (24) 33
Peripheral artery disease 6 (5) 5
Previous stroke 9 (7) 6
Time from onset of symptoms (range) 10 (3–30) 11
Body mass index, kg/m2 (range) 24.7 (23.0–28.6) 26.1
Estimated glomerular filtration rate,
ml/min/1.73 m2 (range)
104 (87–119) 100alues are presented as n (%) or mean  SD unless otherwise indicated.ncremental diagnostic value of copeptin. The diagnostic
ccuracy of troponin T at presentation in the diagnosis of AMI
s quantified by the area under the ROC curve (AUC) was
.86 (95% confidence interval [CI]: 0.80 to 0.92), which was
ignificantly higher than the diagnostic accuracy of copeptin at
resentation (AUC 0.75; 95% CI: 0.69 to 0.81; p  0.009)
Fig. 4). However, the combination of the 2 markers signifi-
antly increased the diagnostic accuracy provided by troponin
alone, with an AUC of 0.97 (95% CI: 0.95 to 0.98; p 
.001) for the combination of troponin T and copeptin. In
ontrast, the combination of troponin T with either the MB
raction of creatine kinase or myoglobin did not result in a
ignificantly higher diagnostic accuracy as compared with
roponin T alone. After adjusting for the variables with
ignificant imbalances across copeptin quartiles, troponin T
nd copeptin invariably remained highly significant predictors
f AMI (for both biomarkers, p  0.001), whereas no other
ariable reached significance.
If patients with ST-segment elevation MI—who are in
eneral triaged on the basis of symptoms and ECG rather
han on initial biomarkers—were excluded from the analy-
is, the combination of troponin T and copeptin yielded
ery similar diagnostic accuracy, as observed in the whole
tudy population (AUC 0.96, 95% CI: 0.94 to 0.98).
apid rule out of AMI using troponin T and copeptin.
able 3 summarizes the diagnostic performance of various
opeptin levels used in conjunction with a troponin T level
0.01 g/l at presentation. A copeptin level 14 pmol/l in
ombination with a troponin T level0.01 g/l would have
orrectly ruled out AMI at presentation with a sensitivity of
8.8%, a negative predictive value of 99.7%, a specificity of
7.1%, and a positive predictive value of 46.2%. In other
s
ptin Quartiles
2
mol/l
2)
Quartile 3
7.4–14.9 pmol/l
(n  122)
Quartile 4
>14.9 pmol/l
(n  121) p Value
6 61 16 69 16 0.001
96 (79) 81 (67) 0.001
70 (57) 86 (71) 0.005
44 (36) 51 (42) 0.502
18 (15) 26 (22) 0.234
25 (21) 32 (26) 0.364
48 (39) 38 (31) 0.077
40 (33) 50 (41) 0.247
29 (24) 37 (31) 0.225
33 (27) 36 (30) 0.774
6 (5) 16 (13) 0.014
5 (4) 16 (13) 0.029
12 (3–39) 7 (3–18) 0.250
28.5) 26.5 (24.2–29.7) 27.4 (23.9–30.0) 0.007
4) 96 (80–114) 73 (52–100) 0.001artile
Cope
artile
7.3 p
 12
9 1
(68)
(50)
(43)
(15)
(30)
(32)
(33)
(22)
(27)
(4)
(5)
(3–72)
(23.1–
(82–11
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June 30, 2009:60–8 Copeptin for the Rapid Rule Out of AMIords, AMI would have correctly been excluded at admis-
ion with only 1 laboratory assessment in 316 of 487
atients (65% of the entire study cohort). Of the remaining
ne-third of patients with positive results for either copeptin
r troponin T or both, roughly one-half of patients finally
eceived the diagnosis of AMI.
iscussion
his prospective study involving unselected patients pre-
enting to the ED with symptoms suggestive of AMI
xamined the value of a dual marker strategy using troponin
, a marker of cardiac necrosis, and copeptin, a marker of
ndogenous stress, for rapid rule out of AMI.
We report 4 major findings: First, copeptin levels were
ignificantly higher in patients with AMI than in patients
ith other adjudicated diagnoses. Second, copeptin was
ignificantly higher in patients with AMI presenting early
o the ED and still negative for troponin T. Conversely,
opeptin provided no additional information in late
resenters who were already positive for troponin T at
dmission. Third, the combination of troponin T and
opeptin resulted in a very high diagnostic accuracy in the
iagnosis of AMI already at presentation (AUC 0.97).
ourth, an algorithm based on the combination of
roponin T and copeptin ruled out AMI at presentation
487 Patients with symptoms 
ECGNo significant ECG abnormalities
n=362
ST-
LBBB not
> 0.01 µg/l
n=24
≤ 0.01 µg/l
n=329
> 0.01 µg/l
n=33
TrTroponin T
AMI
n=18
Copeptin 
9 (5-15)
others
n=15
Copeptin
28 (8-64)
AMI
n=5
Copeptin
61 (37-103)
Minimum
20.8
others
n=324
Copeptin
6 (3-11)
AMI
n=23
Copeptin 
26 (11-57)
others
n=1
Copeptin
35.5
P<0.001
Figure 3 Copeptin Levels According to Admission ECG and Tro
Copeptin values are presented, in pmol/l, as median (interquartile range). AMI  acutith a sensitivity of 98.8% and a negative predictive value 4f 99.7%. Accordingly, continuous ECG monitoring and
erial blood sampling, today needed in all patients to rule
ut AMI, could be limited to the one-third of patients
ositive for either troponin T (0.01 g/l) or copeptin
14 pmol/l), whereas these resources would no longer
e required for patients negative for both markers (nearly
wo-thirds of patients in our cohort).
These findings have important clinical implications. The
apid and reliable exclusion of AMI in patients presenting
ith chest pain is one of the large unmet needs in clinical
edicine. Because of the delayed increase in troponins and
ormal or unspecific ECG findings, 10 million patients
orldwide require prolonged monitoring and serial blood
ampling each year before AMI can safely be excluded. The
dditional costs associated with the remaining diagnostic
ncertainty after the first troponin measurement are esti-
ated to exceed several billion U.S. dollars each year
11,12). Thus, the improvement in the early rule out of
MI offered by copeptin testing may have the potential to
mprove allocation of resources in the ED and to markedly
educe total treatment cost (24). Acute MI could be rapidly
nd reliably ruled out at admission in two-thirds of patients,
nd only the remaining one-third of patients (instead of all
atients) would need monitoring and serial blood sampling,
ith roughly one-half of them (positive predictive value
estive of AMI
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Copeptin for the Rapid Rule Out of AMI June 30, 2009:60–8Cardiac troponins currently are the biomarker of choice for
he serologic diagnosis of AMI (3,25). Our results confirm the
elay of several hours between onset of symptoms and rise of
roponin in AMI observed in previous studies (4,10). In this
tudy, 25% of patients with AMI initially presented with a
roponin T level 0.01 g/l. This rate was identical to that
bserved with a contemporary troponin I assay in a recent
tudy (4). In addition, the AUC for AMI at presentation was
.86 in a prospective study using a novel sensitive troponin I
ssay, which is equal to the AUC of troponin T in our study
26). It is unknown whether the development of even more
ensitive troponin assays will improve the utility of troponin to
apidly rule out AMI, without resulting in a significant increase
n false positive test results (27).
Our data suggest that a dual marker strategy combining
roponin T and copeptin benefits from the integration of
omplementary information provided by pathophysiologi-
ally different processes: troponin T for the detection and
uantification of myocardial necrosis, and copeptin for the
uantification of endogenous stress. It is important to note
hat despite extensive research with markers representing
Figure 4 ROC Curves at Presentation for the Diagnosis of AMI
Area under the receiver-operator characteristic (ROC) curves for troponin T
(blue line) and copeptin (green line) at presentation, and the combination
(red line) of both markers in the diagnosis of acute myocardial infarction (AMI).
Copeptin Value Used With Troponin T <0.01 gat Presentation to Rule Out Acute Myocardial In
Table 3 Copeptin Value Used With Troponinat Presentation to Rule Out Acute M
Copeptin Cutoff Level
(pmol/l)
Sensitivity
(%)
Speci
(%
9 100 62
14 98.8 77
20 96.3 83
24 95.1 86arious pathophysiological pathways including inflamma-
ion, platelet activation, and ischemia, none of the markers
reviously assessed was able to consistently show incremen-
al value in the early rule out of AMI when used in
ombination with troponins (28–32).
Clinical research of the arginine-vasopressin system was
mpaired until very recently by the instability of the active
eptide. The introduction of a novel immunoassay measur-
ng copeptin, the c-terminal part of the vasopressin prohor-
one, provided a unique window into the role of this system
n common medical disorders (18). Research by our group
nd others has suggested that copeptin and therefore the
asopressin system is a major determinant of outcome in
atients with community-acquired pneumonia, exacerbated
hronic obstructive pulmonary disease, sepsis, and AMI
19,33–35). A recent study furthermore showed a correla-
ion between copeptin and the individual stress level (36).
ur findings suggest that endogenous stress occurring with
he onset of AMI results in a rapid release of vasopressin
nd copeptin. It is unknown whether vasopressin/copeptin
ecretion merely reflects the acute endogenous stress reac-
ion associated with AMI (13) or has additional pathophys-
ological beneficial effects, for example, on coronary artery
lood flow (37). With increasing time after onset of symp-
oms, we observed decreasing levels of copeptin, in contrast
o increasing levels of troponin T. The fall in copeptin levels
ay reflect a mechanism of adaptation by the endogenous
tress system facing a continuous stress such as AMI or may
e the consequence of the resolution or at least reduction of
hest pain after the onset of AMI, or both. This extends and
orroborates recent findings in 132 patients with AMI and
lood sampling for 5 days after diagnosis of AMI, showing
copeptin peak with similar levels on day 1 and falling levels
hereafter, until reaching a plateau by day 3 to 5 (19).
In contrast to patients with AMI, patients with unstable
ngina had similar copeptin levels as did patients with other
auses of chest pain. These data suggest that AMI induces
higher level of endogenous stress than unstable angina
oes, potentially related at least in part to the more
rolonged course of chest pain in patients with AMI.
schemia, as long as not accompanied by necrosis (i.e.,
nstable angina), does not seem to be a stronger trigger of
opeptin release than are other causes of chest pain. This
nding is well in agreement with a recent study showing
omparable increases in copeptin levels during exercise in
atients with or without exercise-induced ischemia (38).
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June 30, 2009:60–8 Copeptin for the Rapid Rule Out of AMIopeptin therefore cannot discriminate patients with un-
table angina from patients with nonischemic chest pain.
tudy limitations. First, this is a single-center study.
owever, as patient demographics were comparable to
everal recent studies including consecutive patients with
ymptoms suggestive of AMI (28–30,39), we consider our
esults representative for unselected patient cohorts present-
ng to the ED with suspected AMI. Second, 81 patients
ith AMI is a small number for an AMI rule out claim, and
onfirmation by larger studies is warranted before copeptin
an be adopted into clinical practice. Furthermore, long-
erm follow-up data would be valuable in future studies.
hird, as a prospective observational study, we cannot
uantify exactly the benefit regarding the allocation of
esources in the ED and treatment cost associated with the
ore rapid exclusion of AMI provided by the additional use
f copeptin. Our hypothesis regarding the economic impact
eeds to be confirmed (or rejected) in a randomized con-
rolled trial with time to discharge and treatment cost as
re-defined end points (24). Fourth, further studies, specif-
cally addressing the ability of copeptin to assist with
uiding therapy (e.g., invasive therapy) will be important.
onclusions
opeptin seems to be an ideal partner for cardiac troponins
or the rapid rule out of AMI. The combination of copeptin
nd troponin significantly improved the diagnostic accuracy
or AMI at presentation as compared to troponin alone.
onsequently, the additional use of copeptin may allow for
rapid and accurate rule out of AMI and might obviate the
eed for prolonged monitoring and serial blood sampling in
he ED for the majority of patients. This fundamental
hange in clinical practice may provide the opportunity to
ignificantly improve patient management in the ED and to
educe treatment cost.
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